ArticleInternational journal of surgery (London, England)2026
Celecoxib pretreatment and nab-paclitaxel-associated acute pain syndrome in patients with breast cancer: a prospective, non-randomized controlled clinical study.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTaxane-associated acute pain syndrome (T-APS) is a frequent adverse effect in breast cancer patients undergoing nab-paclitaxel, affecting treatment adherence and quality of life (QoL). We analyzed the effectiveness of preventative celecoxib on T-APS among these patients.
methodsThis non-randomized controlled trial included 270 breast cancer patients receiving nab-paclitaxel who experienced musculoskeletal pain during the first cycle. Subjects were assigned to receive celecoxib (200 mg, administered on Days 1-7) or a placebo. The main outcome measured was the overall incidence of severe T-APS (>5 on a 0-10 scale) during cycles 2-4. Secondary endpoints included the incidence, severity, and duration of T-APS (assessed by the Brief Pain Inventory scale); QoL; peripheral nerve function; and adverse events.
resultsThe overall incidence of severe T-APS was 10.2% in the celecoxib group and 50.0% in the placebo group during cycles 2-4 ( P < 0.001). Mean FACT-B subscale scores were significantly higher in the celecoxib group (101.62, 95% CI: 99.70-103.53; 105.59, 95% CI: 103.57-107.61; and 108.02, 95%CI: 106.18-109.85) than the placebo group (99.02, 95% CI: 97.29-100.76; 99.80, 95% CI: 98.03-101.57; and 99.10, 95% CI: 97.39-100.81) ( P < 0.05). QoL on EORTC QLQ-C30 was also better in the celecoxib group, except for appetite loss, fatigue, and insomnia ( P < 0.05). Following four cycles, the mean scores on the FACT-Ntx subscale in the celecoxib group remained higher (34.10, 95% CI: 33.29-34.91 vs 32.25, 95% CI: 31.63-32.88) ( P < 0.01). Additionally, the incidence of peripheral neuropathy at grade 1 or higher in CTCAE 5.0 was reduced in the celecoxib group (36.7% vs 63.8%, P < 0.001).
conclusionPreventative celecoxib significantly reduced the incidence of severe T-APS and improved QoL in breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.